Enzalutamide
- Generic Name
- Enzalutamide
- Brand Names
- Xtandi, Enzalutamide Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16F4N4O2S
- CAS Number
- 915087-33-1
- Unique Ingredient Identifier
- 93T0T9GKNU
- Background
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieve...
- Indication
Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCRPC). It is also used in combination with talazoparib for the treatment of adult patients with HRR gene-mutated mCRPC.
- Associated Conditions
- Castration Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1500
- Registration Number
- NCT06136650
- Locations
- 🇺🇸
Stanford Cancer Center ( Site 0036), Palo Alto, California, United States
🇸🇬National University Hospital ( Site 1201), Singapore, Central Singapore, Singapore
🇹🇭Chulalongkorn University ( Site 1355), Bangkok, Krung Thep Maha Nakhon, Thailand
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1800
- Registration Number
- NCT06120491
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 201
- Registration Number
- NCT06099769
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California San Francisco (Data collection only), San Francisco, California, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT06096870
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-02-14
- Target Recruit Count
- 50
- Registration Number
- NCT06059118
- Locations
- 🇺🇸
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 51
- Registration Number
- NCT06015321
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Korea, Republic of
An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings
- Conditions
- Interventions
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1375
- Registration Number
- NCT06013475
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2800
- Registration Number
- NCT05968599
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05901649
- Locations
- 🇩🇪
Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz, Germany
🇦🇹Klinikum Wels Grieskirchen, Wels, Austria
🇦🇹Akh Wien, Wien, Austria
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05873192
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.